materi
plasma
obtain
grifol
baxter
hepat
b
viru
hbv
plasma
sampl
collect
komfo
anoky
teach
hospit
kumasi
ghana
report
elsewher
pcr
reagent
obtain
appli
biosystem
unless
otherwis
note
prepar
sampl
untreat
infect
sampl
use
control
infect
platelet
concentr
creat
resuspend
platelet
plasma
pct
pct
platelet
plasma
perform
use
condit
use
intercept
blood
system
baxter
healthcar
briefli
platelet
plasma
treat
amotosalen
uva
viral
dna
extract
preamplif
inhibit
assay
viral
dna
extract
plasma
use
high
pure
viral
nucleic
acid
kit
roch
diagnost
accord
manufactur
instruct
sampl
high
viral
load
dilut
use
plasma
perform
extract
final
concentr
nucleic
acid
within
dynam
rang
qpcr
studi
semiquantit
pcr
dna
extract
infect
plasma
excis
restrict
enzym
xhoi
kpni
result
fragment
devoid
viral
region
insert
pbluescriptii
sk
plasmid
bp
result
plasmid
kb
size
solut
log
use
stock
solut
analysi
perform
control
sampl
primer
sequenc
amplifi
templat
follow
nt
forward
nt
revers
reaction
contain
pcr
buffer
dntp
mmoll
primer
dimethyl
sulfoxid
dna
templat
taq
dna
polymeras
pcr
paramet
min
cycl
min
min
preamplif
hbv
preamplif
perform
control
sampl
viral
dna
amplifi
use
primer
span
region
suffici
conserv
across
genotyp
forward
bp
revers
bp
nt
forward
nt
revers
nt
forward
nt
revers
nt
forward
nt
revers
hbv
forward
bp
hbv
revers
bp
hbv
nt
forward
hbv
nt
revers
hbv
nt
forward
hbv
nt
revers
pcr
mixtur
contain
pcr
buffer
ii
mmoll
mmoll
dntp
primer
u
amplitaq
dna
polymeras
templat
dna
contain
copiesml
use
reaction
pcr
paramet
pcr
initi
incub
min
cycl
min
follow
cycl
min
perform
pcr
gener
bp
cycl
min
use
gener
bp
cycl
min
use
gener
bp
cycl
min
perform
pcr
follow
incub
min
hbv
pcr
paramet
pcr
initi
incub
cycl
preamplif
appli
min
min
increment
everi
cycl
final
step
min
reaction
gener
amplicon
condit
appli
cycl
without
time
increment
amplicon
cycl
preamplif
appli
qpcr
condit
hbv
preamplif
sampl
quantifi
term
intern
unit
per
millilit
use
pcr
viral
dna
quantifi
use
multiplex
qpcr
system
stratagen
technolog
method
describ
elsewher
primer
qpcr
bp
design
basi
sequenc
within
gene
primer
hbv
qpcr
bp
nt
forward
nt
revers
taqman
probe
hbv
nt
forward
hbv
nt
revers
hbv
taqman
probe
fluorogen
probe
vic
appli
biosystem
amplif
perform
duplic
use
brilliant
qpcr
core
reagent
kit
stratagen
accord
manufactur
instruct
initi
incub
min
cycl
min
perform
duplic
serial
dilut
first
intern
standard
parvoviru
dna
nat
assay
nation
institut
biolog
standard
control
nibsc
iu
genomereact
use
refer
curv
quantif
hbv
qpcr
perform
cycl
standard
quantif
intern
unit
per
millilit
nibsc
four
serial
dilut
made
refer
curv
immunospot
elispot
assay
determin
infect
plasma
platelet
evalu
infect
describ
elsewher
briefli
viabl
viru
titer
determin
infect
cell
cell
cell
induc
differenti
cell
infect
serial
dilut
control
pct
sampl
transfer
elispot
plate
coat
polyclon
antibodi
protein
dako
elispot
plate
incub
h
cell
wash
bound
antigen
detect
develop
silver
stain
visual
plate
reader
count
data
analysi
elispot
assay
observ
viral
infect
titer
use
calcul
log
number
inactiv
viru
pct
unit
calcul
follow
total
number
spot
observ
well
divid
dilut
divid
volum
materi
plate
dilut
log
reduct
analyz
log
controltr
vitro
efficaci
pathogen
inactiv
demonstr
semiquantit
pcr
determin
extent
pcr
inhibit
result
photochem
treatment
amotosalen
uva
dose
pct
semiquantit
pcr
use
establish
detect
sensit
measur
effect
pct
figur
pcr
approach
appli
condit
amplif
fragment
long
enough
amplicon
detect
modif
viral
genom
caus
pct
rang
sensit
log
accuraci
differ
standard
use
demonstr
assay
rang
standard
subject
amplif
long
amplicon
use
detect
pcr
product
densitometri
band
show
correl
band
intens
concentr
amplifi
templat
figur
standard
base
pcr
increas
input
titer
genom
plasmid
plasmid
encod
entir
genom
minu
region
basi
standard
lower
limit
sensit
assay
log
copi
demonstr
detect
amplifi
band
input
titer
log
copi
figur
lane
b
densitometri
dna
gel
show
amplifi
signal
becam
stronger
increas
amount
input
reach
plateau
input
titer
log
figur
lane
f
higher
input
titer
log
result
increas
densitometri
dna
band
compar
input
band
figur
lane
g
h
demonstr
linear
dynam
rang
figur
lane
corrobor
log
rang
shown
plasmid
rel
rang
detect
also
demonstr
use
untreat
viral
extract
shown
increas
input
titer
figur
lowest
concentr
detect
correspond
input
titer
log
viral
extract
subject
pct
assess
effect
amplif
figur
lane
show
untreat
viral
extract
compar
lane
lane
l
depict
undilut
pct
viral
extract
demonstr
pct
caus
complet
pcr
inhibit
detect
band
pct
lane
amplif
demonstr
reduct
genom
modifi
pcr
assay
quantit
method
measur
pcr
inhibit
pct
convent
pcr
approach
demonstr
compar
method
detect
chang
signal
amplif
viral
sampl
treat
pct
versu
untreat
control
sampl
lack
quantit
analysi
measur
pcr
inhibit
pct
convent
qpcr
unsuccess
inabl
assay
support
long
amplicon
modifi
approach
involv
preamplif
larg
pcr
product
follow
qpcr
short
amplicon
develop
detect
inactiv
pct
purpos
combin
use
pcr
amplicon
accur
detect
whether
dna
adduct
form
viral
genom
quantit
method
compar
differ
untreat
pct
sampl
figur
list
preamplif
condit
accord
amplicon
size
cycl
number
preamplif
pcr
condit
sever
amplicon
length
vari
bp
kb
adjust
gener
equal
amount
final
pcr
product
measur
use
short
qpcr
amplicon
bp
qpcr
standard
curv
preamplif
product
demonstr
accur
normal
preamplif
condit
compar
preamplif
control
qpcr
baselin
control
preamplif
figur
show
case
preamplif
condit
creat
rang
preamplif
compar
baselin
control
pcr
amplif
plasma
inhibit
pct
preamplif
qpcr
assay
detect
inhibit
viral
amplif
pct
limit
detect
figur
log
inhibit
amplif
increas
longer
amplicon
demonstr
need
preamplif
step
amplicon
kb
detect
maximum
effect
pct
amplicon
compar
evalu
pct
inactiv
dna
modif
genom
caus
pct
correl
viral
replic
function
demonstr
quantit
approach
measur
pathogen
inactiv
increas
efficaci
amotosalen
pla
preincub
nonenvelop
viru
preincub
viru
amotosalen
could
increas
drug
exposur
avail
viral
genom
time
cours
increas
incub
period
amotosalen
uva
illumin
show
log
inhibit
amplif
reduct
infect
could
improv
longer
preincub
figur
correl
pcr
inhibit
infect
measur
pathogen
inactiv
illustr
correl
result
assay
plot
figur
graph
illustr
strong
correl
result
show
potenti
use
preamplif
qpcr
assay
extrapol
reduct
viral
infect
exampl
use
assay
log
inhibit
measur
qpcr
inhibit
correspond
log
reduct
infect
measur
elispot
inactiv
platelet
concentr
pct
effort
determin
whether
preamplif
pcr
assay
could
detect
inhibit
presenc
cellular
compon
inactiv
studi
figur
platelet
concentr
plasma
pct
inhibit
amplif
platelet
log
effect
increas
preincub
contamin
plasma
amotosalen
uva
similar
result
plasma
demonstr
correl
preamplif
pcr
assay
infect
result
sampl
measur
assay
directli
compar
valu
corrobor
result
pct
plasma
strong
correl
elispot
preamplif
pcr
inhibit
assay
case
preamplif
pcr
log
inhibit
would
equal
reduct
infect
log
preamplif
pcr
inhibit
assay
measur
inactiv
hbv
pct
assay
develop
extend
pathogen
vitro
test
exist
hbv
use
model
determin
whether
assay
could
also
detect
efficaci
pct
plasma
whether
improv
could
made
dynam
rang
assay
figur
show
preamplif
condit
amplicon
size
number
cycl
illustr
number
preamplif
cycl
directli
determin
rang
log
inhibit
possibl
control
perform
measur
dynam
rang
test
hbv
amplif
hbv
primer
gener
amplicon
increas
length
preamplif
pcr
condit
normal
produc
number
copi
figur
case
hbv
preamplif
cycl
normal
cycl
amplicon
mathemat
preamplif
cycl
assumpt
effici
would
yield
copi
equal
log
practic
effici
pcr
reach
control
show
rang
log
inhibit
log
therefor
maximum
log
inhibit
hbv
broader
rang
detect
possibl
condit
set
hbv
set
increas
number
preamplif
cycl
inhibit
hbv
amplif
limit
detect
pct
preamplif
pcr
assay
develop
hbv
use
figur
treatment
sampl
pct
caus
inhibit
amplif
limit
detect
log
graph
show
amplicon
length
kb
necessari
detect
effect
pct
develop
method
blood
product
would
allow
safer
blood
transfus
present
blood
bank
test
presenc
specif
pathogen
test
limit
detect
avail
sensit
time
requir
product
releas
use
pathogen
inactiv
would
provid
ideal
scenario
broad
spectrum
bacteria
virus
parasit
could
inactiv
fewer
blood
product
would
wast
establish
effect
technolog
biolog
assay
standard
determin
reduct
infecti
titer
pathogen
test
system
current
avail
frequent
limit
complic
biolog
assay
time
consum
labor
intens
pathogen
vitro
assay
exist
present
studi
develop
novel
preamplif
qpcr
inhibit
assay
use
estim
reduct
viral
infect
parallel
associ
pcr
amplif
infect
appli
inactiv
studi
differ
virus
equat
result
particular
assay
result
anoth
assay
pcr
assay
allow
quicker
result
determin
presenc
pathogen
sampl
also
measur
amplif
capabl
pathogen
inactiv
determin
whether
treatment
disrupt
replic
function
viru
use
faster
test
method
one
also
studi
close
biolog
capabl
viru
capsid
penetr
dose
effect
preincub
paramet
optim
assay
analysi
vari
length
pcr
product
determin
amplicon
size
necessari
detect
pct
inactiv
amplicon
length
increas
preamplif
cycl
necessari
produc
equal
number
copi
decreas
replic
effici
longer
pcr
product
normal
preamplif
reaction
allow
direct
comparison
amplicon
length
determin
condit
best
suit
studi
pathogen
inactiv
pct
introduc
preamplif
qpcr
inhibit
assay
potenti
inactiv
test
studi
also
reveal
way
improv
assay
increas
sensit
rang
exampl
increas
number
preamplif
cycl
would
broaden
log
sensit
assay
demonstr
use
condit
appli
detect
hbv
inhibit
compar
amount
parent
dna
baselin
increas
amplif
rang
would
provid
greater
potenti
detect
finer
differ
control
pct
sampl
mathemat
true
preamplif
condit
normal
equal
smallest
amplicon
subject
preamplif
cycl
preamplif
cycl
hbv
assumpt
pcr
effici
preamplif
cycl
increas
copi
number
amplicon
log
preamplif
cycl
assumpt
effici
would
yield
copi
log
case
hbv
pcr
effici
therefor
log
rang
log
perfect
imposit
preamplif
product
viru
show
pcr
effici
decreas
increas
amplicon
size
thu
maintain
preamplif
rang
cycl
need
amplicon
amplicon
amplicon
control
establish
rang
log
inhibit
assay
therefor
log
inhibit
amplif
log
plasma
sampl
would
demonstr
complet
inactiv
limit
detect
anoth
method
increas
detect
rang
assay
shift
baselin
curv
qpcr
amplicon
detect
preamplif
differ
control
pct
sampl
typic
small
bp
qpcr
step
amplifi
parent
dna
regardless
whether
anoth
region
genom
statist
pct
caus
everi
bp
thu
likelihood
qpcr
primer
amplifi
region
lack
adduct
high
therefor
although
parent
dna
pct
qpcr
assay
fail
detect
use
longer
qpcr
target
would
decreas
statist
occurr
primer
amplifi
chanc
region
adduct
would
improv
assay
increas
log
rang
inactiv
possibl
without
increas
number
preamplif
cycl
result
preamplif
qpcr
assay
correl
elispot
assay
plasma
platelet
signifi
predict
infect
linear
relationship
identifi
use
assay
measur
effect
min
preincub
amotosalen
illumin
uva
instanc
preamplif
qpcr
inhibit
equival
reduct
infect
establish
refer
curv
qpcr
infect
one
extrapol
level
inactiv
infect
perform
qpcr
assay
conclus
novel
pcr
inhibit
assay
effect
demonstr
pct
inactiv
hbv
blood
product
